Actuate Therapeutics Inc. (ACTU) Short-Term Debt to Equity

Actuate Therapeutics, Inc. (ACTU) relies on GSK-3beta inhibitor patents to combat glioblastoma while navigating strict FDA oversight. Historical price action on GURU.Markets, where the indicator stands at 0.00, confirms the asset's status. High clinical costs and the risk of small molecule test failures limit competition, while exclusive intellectual property rights ensure a steady revenue stream.

Short-term debt-to-equity determines the proportion of liabilities with a maturity of over one year within the equity structure. This metric measures financial leverage, where an increasing ratio elevates default risk by reducing balance sheet stability. By analyzing the dynamics of short-term liabilities to equity on GURU.Markets, an investor can discern the actual debt load. For Actuate Therapeutics, Inc. (ACTU), this is critical due to its reliance on speculative financing during the development of oncology drugs.